ERBB2 and breast carcinoma: Whereas it remains challenging to determine with certainty whether the response was solely attributed to cabozantinib or a combination of these therapies, addition of a RET inhibitor led to a clinical response in this patient with treatment-refractory ER+/HER2-overexpressing breast cancer presenting a NCOA4-RET fusion [72].